Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

Affiliations

• ¹ University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.
• ² Massachusetts General Hospital, Boston, MA, USA.
• ³ Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
• ⁴ Indiana University Health Goshen Center for Cancer Care, Goshen, IN, USA.
• ⁵ Segal Cancer Centre, Montreal, Quebec, Canada.
• ⁶ Jewish General Hospital, Montreal, Quebec, Canada.
• ⁷ McGill University, Montreal, Quebec, Canada.
• ⁸ Westmead Hospital, Sydney, New South Wales, Australia.
• ⁹ Blacktown Hospital, Sydney, New South Wales, Australia.
• ¹⁰ The University of Sydney, Sydney, New South Wales, Australia.
• ¹¹ Melanoma Institute Australia, Sydney, New South Wales, Australia.
• ¹² Auckland District Health Board, Auckland, New Zealand.
• ¹³ Royal North Shore Hospital, Sydney, New South Wales, Australia.
• ¹⁴ Mater Hospital, Sydney, New South Wales, Australia.
• ¹⁵ Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹⁶ University of California, Los Angeles, Los Angeles, CA, USA.
• ¹⁷ Novartis, East Hanover, NJ, USA.
• ¹⁸ Merck & Co., Inc., Kenilworth, NJ, USA.
• ¹⁹ The Angeles Clinic and Research Institute, Los Angeles, CA, USA.